In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse

Ferdinando Nicoletti, Pierluigi Meroni, Roberto Di Marco, Wilma Barcellini, Maria Orietta Borghi, Marisa Gariglio, Angela Mattina, Sebastiano Grasso, Santo Landolfo

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The effects of the in vivo treatment with a mAB (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalImmunopharmacology
Volume24
Issue number1
DOIs
Publication statusPublished - 1992

Fingerprint

Inbred MRL lpr Mouse
Lupus Nephritis
Interferon-gamma
Monoclonal Antibodies
Survival
Incidence
Theoretical Models
Therapeutics

Keywords

  • Autoimmune disease
  • IFN-gamma, anti-gamma-IFN mAB
  • MRL-lpr mouse
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Pharmacology

Cite this

In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. / Nicoletti, Ferdinando; Meroni, Pierluigi; Di Marco, Roberto; Barcellini, Wilma; Borghi, Maria Orietta; Gariglio, Marisa; Mattina, Angela; Grasso, Sebastiano; Landolfo, Santo.

In: Immunopharmacology, Vol. 24, No. 1, 1992, p. 11-16.

Research output: Contribution to journalArticle

Nicoletti, Ferdinando ; Meroni, Pierluigi ; Di Marco, Roberto ; Barcellini, Wilma ; Borghi, Maria Orietta ; Gariglio, Marisa ; Mattina, Angela ; Grasso, Sebastiano ; Landolfo, Santo. / In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. In: Immunopharmacology. 1992 ; Vol. 24, No. 1. pp. 11-16.
@article{eda5247dd1104774ace88eb64a904c71,
title = "In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse",
abstract = "The effects of the in vivo treatment with a mAB (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.",
keywords = "Autoimmune disease, IFN-gamma, anti-gamma-IFN mAB, MRL-lpr mouse, Systemic lupus erythematosus",
author = "Ferdinando Nicoletti and Pierluigi Meroni and {Di Marco}, Roberto and Wilma Barcellini and Borghi, {Maria Orietta} and Marisa Gariglio and Angela Mattina and Sebastiano Grasso and Santo Landolfo",
year = "1992",
doi = "10.1016/0162-3109(92)90064-J",
language = "English",
volume = "24",
pages = "11--16",
journal = "Immunopharmacology",
issn = "0162-3109",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse

AU - Nicoletti, Ferdinando

AU - Meroni, Pierluigi

AU - Di Marco, Roberto

AU - Barcellini, Wilma

AU - Borghi, Maria Orietta

AU - Gariglio, Marisa

AU - Mattina, Angela

AU - Grasso, Sebastiano

AU - Landolfo, Santo

PY - 1992

Y1 - 1992

N2 - The effects of the in vivo treatment with a mAB (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.

AB - The effects of the in vivo treatment with a mAB (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.

KW - Autoimmune disease

KW - IFN-gamma, anti-gamma-IFN mAB

KW - MRL-lpr mouse

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0026756611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026756611&partnerID=8YFLogxK

U2 - 10.1016/0162-3109(92)90064-J

DO - 10.1016/0162-3109(92)90064-J

M3 - Article

C2 - 1452442

AN - SCOPUS:0026756611

VL - 24

SP - 11

EP - 16

JO - Immunopharmacology

JF - Immunopharmacology

SN - 0162-3109

IS - 1

ER -